Angiogenesis

, Volume 6, Issue 2, pp 121–128 | Cite as

Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo

  • Masakazu Toi
  • Hiroko Bando
  • Cheppail Ramachandran
  • Steven J. Melnick
  • Atsushi Imai
  • Rose S. Fife
  • Raymond Eric Carr
  • Tsutomu Oikawa
  • Ephraim Philip Lansky
Article

Abstract

We previously showed pomegranate seed oil and fermented juice polyphenols to retard oxidation and prostaglandin synthesis, to inhibit breast cancer cell proliferation and invasion, and to promote breast cancer cell apoptosis. Here we evaluated the anti-angiogenic potential of these materials in several ways. We checked a possible effect on angiogenic regulation by measuring vascular endothelial growth factor (VEGF), interleukin-4 (IL-4) and migration inhibitory factor (MIF) in the conditioned media of estrogen sensitive (MCF-7) or estrogen resistant (MDA-MB-231) human breast cancer cells, or immortalized normal human breast epithelial cells (MCF-10A), grown in the presence or absence of pomegranate seed oil (SESCO) or fermented juice polyphenols (W). VEGF was strongly downregulated in MCF-10A and MCF-7, and MIF upregulated in MDA-MB-231, overall showing significant potential for downregulation of angiogenesis by pomegranate fractions. An anti-proliferative effect on angiogenic cells was shown in human umbilical vein endothelial cell (HUVEC) and in myometrial and amniotic fluid fibroblasts, and inhibition of HUVEC tubule formation demonstrated in an in vitro model employing glass carrier beads. Finally, we showed a significant decrease in new blood vessel formation using the chicken chorioallantoic membrane (CAM) model in vivo. 'In sum, these varied studies employing different models in different laboratories overall demonstrate for the first time an anti-angiogenic potential of pomegranate fractions, suggesting further in vivo and clinical investigations (for updates: info@rimonest.com).

angiogenesis breast cancer chemoprevention MIF Punica granatum VEGF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eatock MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 2000; 26: 191–204.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeffer U, Ferrari N, Morini M et al. Antiangiogenic activity of chemopreventive drugs. Int J Biol Markers 2003; 18: 70–4.PubMedGoogle Scholar
  3. 3.
    Scappaticci FA. The therapeutic potential of novel antiangiogenic therapies. Expert Opin Invest Drugs 2003; 12: 923–32.CrossRefGoogle Scholar
  4. 4.
    Auerbach R, Lewis R, Shinners B et al. Angiogenesis assays: A critical overview. Clin Chem 2003; 49: 32–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim ND, Mehta R, Yu W et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Fotsis T, Pepper MS, Montesano R et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998; 12: 649–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Le Marchand L. Cancer preventive effects of flavonoids - a review. Biomed Pharmacother 2002; 56: 296–301.PubMedCrossRefGoogle Scholar
  8. 8.
    Sartippour MR, Heber D, Zhang L et al. Inhibition of fibroblast growth factors by green tea. Int J Oncol 2002; 21: 487–91.PubMedGoogle Scholar
  9. 9.
    Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol 1999; 66: 11–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Masso-Welch PA, Zangani D, Ip C et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002; 62: 4383–9.PubMedGoogle Scholar
  11. 11.
    Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002; 17: 599–621.PubMedGoogle Scholar
  12. 12.
    Hartlapp I, Abe R, Saeed RW et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Kapiteijn K, Koolwijk P, Van Der Weiden R et al. Steroids and cytokines in endometrial angiogenesis. Anticancer Res 2001; 21: 4231–42.PubMedGoogle Scholar
  14. 14.
    Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer 2000; 7: 181–6.PubMedGoogle Scholar
  16. 16.
    Bando H, Matsumoto G, Bando M et al. Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res 2002; 93: 389–96.PubMedGoogle Scholar
  17. 17.
    Imamura M. Extracellular matrix components and angiogenesis. Nippon Yakurigaku Zasshi 1996; 107: 153–60.PubMedGoogle Scholar
  18. 18.
    Ueno T, Toi M, Saji H et al. The role of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival of human breast cancer. Clin Cancer Res 2000; 6: 3282–9.PubMedGoogle Scholar
  19. 19.
    Oikawa T, Sasaki T, Nakamur M et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Fife RS, Sledge Jr GW, Sissons S et al. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000; 153: 75–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Oikawa T, Hirotani K, Nakamura O et al. A highly potent antiangiogenic activity of retinoids. Cancer Lett 1989; 48: 157–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Oikawa T, Hirotani K, Ogasawara H et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cellinduced angiogenesis. Eur J Pharmacol 1999; 386: 33–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy. Angiogenesis 2001; 4: 259–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Maulik N, Das D. Redox signaling in vascular angiogenesis (1,2). Free Radic Biol Med 2002; 33: 1047.PubMedCrossRefGoogle Scholar
  26. 26.
    Leek RD, Talks KL, Pezzella F et al. Relation of hypoxiainducible factor-2 alpha (HIF-2 alpha) expression in tumorinfiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002; 62: 1326–9.PubMedGoogle Scholar
  27. 27.
    Sasaki H, Ray PS, Zhu L et al. Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: Possible role of NFkappaB. Toxicology 2000; 155: 27–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Schubert SY, Neeman I, Resnick N. A novel mechanism for the inhibition of NFkB activation in vascular endothelial cells by natural antioxidants. FASEB J 2002; 16: 1931–3.PubMedGoogle Scholar
  29. 29.
    Sharaf A, Nigm SAR. The oestrogenic activity of pomegranate seed oil. J Endocrinol 1964; 29: 91–2.PubMedGoogle Scholar
  30. 30.
    Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002; 966: 143–57.PubMedCrossRefGoogle Scholar
  31. 31.
    Gargett CE, Zaitseva M, Bucak K et al. 17Beta-estradiol upregulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: Role of estrogen receptor-alpha and-beta. J Clin Endocrinol Metab 2002; 87: 4341–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Galea E, Santizo R, Feinstein DL et al. Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport 2002; 13: 1469–72.PubMedCrossRefGoogle Scholar
  33. 33.
    White RE. Estrogen and vascular function. Vasc Pharmacol 2002; 38: 73–80.CrossRefGoogle Scholar
  34. 34.
    Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 2002; 9: 39–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Nugteren DH, Christ-Hazelhof E. Naturally occurring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis. Prostaglandins 1987; 33: 403–17.PubMedCrossRefGoogle Scholar
  36. 36.
    Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330–4.PubMedGoogle Scholar
  37. 37.
    Meyer-Siegler K. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4–2b prostate cancer cells. Mol Med 2001; 7: 850–60.PubMedGoogle Scholar
  38. 38.
    Lansky EP, Jiang WG, Mo H et al. Therapeutic synergy in pomegranate. Poster presented at the 94th Annual Meeting of the American Association for Cancer Research, July 11-14, 2003, Washington, DC.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Masakazu Toi
    • 1
  • Hiroko Bando
    • 1
  • Cheppail Ramachandran
    • 2
  • Steven J. Melnick
    • 2
  • Atsushi Imai
    • 3
  • Rose S. Fife
    • 4
  • Raymond Eric Carr
    • 4
  • Tsutomu Oikawa
    • 5
  • Ephraim Philip Lansky
    • 6
  1. 1.Department of SurgeryTokyo Metropolitan Komagome HospitalTokyoJapan
  2. 2.Miami Children's HospitalResearch InstituteMiamiUSA
  3. 3.Department of Obstetrics and GynecologyGifu University, School of MedicineTsukasamachi, GifuJapan
  4. 4.Department of MedicineIndiana University School of MedicineIndianapolisUSA
  5. 5.Department of Molecular OncologyThe Tokyo Metropolitan Institute of Medical Science (Rinshoken), Tokyo Metropolitan Organization for Medical ResearchTokyoJapan
  6. 6.Horev CenterRimonest LtdHaifaIsrael

Personalised recommendations